Cooperation between fundinfo and UBS Fondcenter for Fund Data Management
UBS AG and its group company Fondcenter AG have commissioned fundinfo AG to procure and source fund data from fund providers and asset managers. In order to provide efficient, legally compliant investment advice, UBS Fondcenter's external and internal partners require on-demand access to complete, accurate and up-to-date fund information, including MiFID II and PRIIPs data. They also rely on the openfunds standard for fund data that was launched and is being continuously enhanced by UBS Fondcenter, Credit Suisse and Julius Bär.
"fundinfo has many years of experience in the procurement, validation and distribution of fund information and meets our high quality requirements", says Christophe Hefti, head UBS Fondcenter at UBS Asset Management. "By partnering with fundinfo, we can concentrate on our core competencies and expand our range of services, including data preparation. At the same time, we are providing fund providers with an experienced partner for high-quality fund data and document management."
“After working successfully with UBS Fondcenter for many years in the area of fund document management, we are pleased and proud that UBS Fondcenter has now placed their trust in fundinfo to perform their fund data management” says Jan Giller, Head of Sales & Marketing at fundinfo. "It is a privilege and a strong testament to our capabilities that the largest asset manager in Switzerland has chosen to work with fundinfo to procure their fund data".
Fund providers are requested to ensure that their static fund data is provided correctly and promptly to fundinfo according to the openfunds data standard (www.openfunds.org). The openfunds standard was initiated by the fund and banking industries. Currently the openfunds Association has 48 active and informational members. Information about fundinfo’s Data Dissemination Service can be found by visiting about.fundinfo.com, or clicking on this short video.
About fundinfo AG
fundinfo AG hosts one of the leading international platforms for information and mandatory publications of investment funds. The platform www.fundinfo.com strengthens the network between fund houses, fund distributors and investors and is recognised by financial market supervisory authorities for mandatory publications. The service is available in Europe and Asia, and covers thousands of funds from the world’s largest fund houses. Founded in 2005 and headquartered in Zürich, Switzerland, fundinfo AG has offices in Berlin, Frankfurt, Hong Kong, London, Madrid, Paris and Singapore.
About Fondcenter AG
Fondcenter AG, a group company of UBS AG, is the leading fund platform in Switzerland and one of the most important in Europe and Asia. Since 1993, UBS Fondcenter has brought together around 300 distribution partners – mainly banks, insurance companies and regulated financial institutions from Switzerland, Europe and Asia – with around 400 fund providers. In addition to its head office in Zurich, UBS Fondcenter now has new offices in Frankfurt and Hong Kong.
Photos and logos: https://about.fundinfo.com/en/news/photos-and-logos/
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Beko Becomes the Naming Partner of Fenerbahçe Men's Basketball Team19.12.2018 13:00 | Tiedote
To forge its support to sports and healthy living, Beko is now the naming partner of Fenerbahçe Men's Basketball Team. Beko has been supporting basketball teams in Turkish Basketball League and also sponsored the European Basketball Championship for many years and now it takes on the naming partnership of Fenerbahçe Men's Basketball Team for 2.5 years. This new naming partnership agreement focuses on “Eat Like A Pro” – an initiative launched by Beko to fight childhood obesity. Through this collaboration, Beko plans to expand the scope of the campaign to promote healthy eating habits among children by advertising their hero basketball players as role models. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181219005026/en/ Beko Becomes Naming Partner of Fenerbahce Men’s Basketball Team (Photo: Business Wire) Beko, a leading white goods brand providing products and services in more than 130 countries, returns to investing in bas
Mopria Powers IPP Print Solution in Windows 10 Update19.12.2018 11:00 | Tiedote
The Mopria® Alliance, a global non-profit membership organization providing universal standards and solutions for print and scan, today announced that Microsoft, a member of the Mopria Alliance, has implemented an IPP printing solution based on the Mopria standard, in the latest version of the Windows 10 operating system. Mopria is a set of standards offering simple and seamless printing to millions of certified printers and multi-function printers. Beginning with Windows 10 October 2018 Update, Windows added support for Mopria certified printers. When users install a new printer and Windows Update is not available, Windows will automatically install the Mopria certified printers. This eliminates the need for users to install any additional software or drivers, allowing them to print easily, regardless of the printer’s brand. “Implementing the Mopria standard in the most recent Windows Update enables us to continue to modernize the printing process for our customers,” said David Lemson
Chugai's Satralizumab Receives FDA Breakthrough Therapy Designation for Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders19.12.2018 11:00 | Tiedote
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Chugai’s anti-interleukin-6 (IL-6) receptor humanized recycling antibody satralizumab, an investigational medicine for neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD). “Satralizumab is a recycling antibody created utilizing Chugai’s proprietary antibody engineering technologies. We are delighted by the FDA’s designation for this innovative antibody based on the results of a Chugai-initiated global Phase III study” said Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit, Dr. Yasushi Ito. “Satralizumab is designed to inhibit signaling of the inflammatory cytokine IL-6, which is known to play a role in the pathogenesis of NMO/NMOSD. We continue our efforts to hopefully bring satralizumab as a new treatment option as soon as possible to people living with this devastating disease
Chugai’s Satralizumab Meets Primary Endpoint in Phase III Monotherapy Study in NMOSD19.12.2018 11:00 | Tiedote
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced that a phase III monotherapy study of satralizumab (development code: SA237), SAkuraStar Study (NCT02073279) for the treatment of neuromyelitis optica spectrum disorder (NMOSD), which currently has no approved treatments, has achieved the primary endpoint. The primary endpoint was time to first protocol-defined relapse in the double-blind period. A statistically significant reduction in the risk of relapse was confirmed in patients who received satralizumab, compared to those who received placebo. Furthermore, the safety profile of satralizumab was consistent with that seen in previous studies. Further details will be presented at a future medical meeting. “We are pleased that satralizumab showed benefits also in a monotherapy setting following the previous results as add-on to baseline treatment in patients with NMOSD,” said Dr. Yasushi Ito, Chugai’s Executive Vice President, Co-Head of Project & Lifecycle Management Unit. “We wil
SES Successfully Placed EUR 400 Million Multi-Tranche Schuldschein Loan19.12.2018 10:50 | Tiedote
SES S.A., the world’s leading satellite operator, has completed the syndication of Schuldschein Loans for a total amount of EUR 400 million, comprising a EUR 150 million 5.5-year floating tranche at Euribor 6 months plus 0.80% and a EUR 250 million 7-year fixed rate tranche with a coupon of 1.71%. SES is rated Baa2/BBB- (both with stable outlook). The Schuldschein loan was upsized from the initially marketed size and was placed with several European and Asian institutions. The proceeds will support SES’ general corporate purposes and the refinancing of existing debt maturities which include a USD 500 million 144A bond with a coupon of 2.5% and a final maturity date of 25 March 2019. Andrew Browne, Chief Financial Officer of SES, commented: “We are pleased to have secured this financing at very attractive terms and expanding our investor base while extending our debt maturity profile, where we now have no further senior debt maturities to be financed until early 2020.” BNP Paribas, ING
Bentall Kennedy and GreenOak Real Estate Announce Merger to Form Bentall GreenOak, Global Real Estate Investment Platform19.12.2018 10:39 | Tiedote
Bentall Kennedy and GreenOak Real Estate (“GreenOak”) announced today the signing of an agreement to merge the two firms into a leading global real estate investment platform. The combined entity will be named Bentall GreenOak. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181218005992/en/ GreenOak Co-Founders, John Carrafiell and Sonny Kalsi, existing GreenOak senior management and GreenOak’s strategic partner Tetragon Financial Group Limited will all continue to hold significant ownership stakes in Bentall GreenOak. Bentall Kennedy’s senior management team will also acquire a meaningful ownership position in the combined firm. Bentall GreenOak will be majority-owned by Sun Life Financial (“Sun Life”) and will operate under Sun Life Investment Management, the alternative asset management arm of Sun Life. Sun Life has committed significant co-investment capital to support the growth of Bentall GreenOak and to enhance the fi
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme